LEXINGTON, Mass.--(BUSINESS WIRE)--T2 Biosystems, a company developing direct detection products enabling superior diagnostics, today announced the initiation of the direcT2 clinical trial of T2Candida®, T2 Bio’s flagship product for the rapid and sensitive identification of five species of Candida. The direcT2 trial will provide data to support a regulatory submission for T2Candida. T2Candida uses the Company’s proprietary T2MR® technology to detect the presence of Candida, a fungal pathogen known to cause sepsis, directly from whole blood in approximately three hours.
Help employers find you! Check out all the jobs and post your resume.
